Edition:
United Kingdom

Income Statements: Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

0.70USD
14 Jun 2019
Change (% chg)

$-0.01 (-1.56%)
Prev Close
$0.71
Open
$0.72
Day's High
$0.74
Day's Low
$0.70
Volume
228,967
Avg. Vol
1,047,901
52-wk High
$3.58
52-wk Low
$0.50

Interim Income Statement
View: AnnualInterim

In Millions ofU.S. Dollars
(except for per share items)
2019
2019-03-31
Period Length
3 Months
Revenue 1.6
Other Revenue, Total --
Total Revenue 1.6
Cost of Revenue, Total --
Gross Profit --
Selling/General/Admin. Expenses, Total 2.5
Research & Development 6.9
Depreciation/Amortization --
Interest Expense, Net - Operating --
Interest/Investment Income - Operating --
Interest Expense(Income) - Net Operating --
Unusual Expense (Income) 0.0
Other Operating Expenses, Total --
Total Operating Expense 9.3
Operating Income (7.7)
Interest Expense, Net Non-Operating (0.6)
Interest/Invest Income - Non-Operating 8.8
Interest Income(Exp), Net Non-Operating --
Gain (Loss) on Sale of Assets --
Other, Net --
Net Income Before Taxes 0.6
Provision for Income Taxes --
Net Income After Taxes 0.6
Minority Interest --
Equity In Affiliates --
U.S. GAAP Adjustment --
Net Income Before Extra. Items 0.6
Accounting Change --
Discontinued Operations --
Extraordinary Item --
Tax on Extraordinary Items --
Net Income 0.6
Preferred Dividends --
General Partners' Distributions --
Miscellaneous Earnings Adjustment --
Pro Forma Adjustment --
Interest Adjustment - Primary EPS --
Income Available to Com Excl ExtraOrd 0.6
Income Available to Com Incl ExtraOrd 0.6
Basic Weighted Average Shares 132.30
Basic EPS Excluding Extraordinary Items 0.004
Basic EPS Including Extraordinary Items 0.004
Dilution Adjustment --
Diluted Weighted Average Shares 132.83
Diluted EPS Excluding ExtraOrd Items 0.004
Diluted EPS Including ExtraOrd Items 0.004
DPS - Common Stock Primary Issue 0.000
Gross Dividends - Common Stock --
Total Special Items 0.0
Normalized Income Before Taxes 0.6
Effect of Special Items on Income Taxes 0.0
Inc Tax Ex Impact of Sp Items 0.0
Normalized Income After Taxes 0.6
Normalized Inc. Avail to Com. 0.6
Basic Normalized EPS 0.004
Diluted Normalized EPS 0.004

BRIEF-Aveo Pharmaceuticals Says Co Entered Agreement With Novartis International Pharmaceutical Regarding Aveo's AV380 Program

* AVEO PHARMACEUTICALS INC - ON DEC. 18, AVEO ENTERED AGREEMENT WITH NOVARTIS INTERNATIONAL PHARMACEUTICAL REGARDING AVEO’S AV380 PROGRAM